CD73 as a potential opportunity for cancer immunotherapy

Author:

Ghalamfarsa Ghasem1,Kazemi Mohammad Hossein23ORCID,Raoofi Mohseni Sahar2,Masjedi Ali45,Hojjat-Farsangi Mohammad67ORCID,Azizi Gholamreza8,Yousefi Mehdi9,Jadidi-Niaragh Farhad910

Affiliation:

1. Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran

2. Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

3. Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

5. Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

6. Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden

7. Department of Immunology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran

8. Non‐Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran

9. Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

10. Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3